Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOL-3021 in New Onset Type 1 Diabetes
NCT03794973Phase 2Withdrawn
- Sponsor
- Tolerion
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing TOL-3021 with Placebo (2 arms). Primary endpoint: Treatment effect on log-transformed Mixed Meal Tolerance Test (MMTT) C-peptide Area Under the Curve (AUC) at 52 weeks. Planned start Dec 2019; status: withdrawn.
02
Drugs
TOL-3021
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03794973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03794973.